HCmed Innovations Co's EPS (Basic) for the
three
months ended in Dec. 2025 was NT$0.25.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.85.
During the past 3 years, the average EPS without NRIGrowth Rate was 16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 5 years, HCmed Innovations Co's highest 3-Year average EPS without NRI Growth Rate was 16.00% per year. The lowest was -4.50% per year. And the median was 5.75% per year.
HCmed Innovations Co (TPE:6934) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
HCmed Innovations Co EPS (Diluted) Related Terms
HCmed Innovations Co EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for HCmed Innovations Co's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6934 vs ABT, SYK, MDT: EPS (Diluted) Comparison
For the Medical Devices subindustry, HCmed Innovations Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCmed Innovations Co PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where HCmed Innovations Co's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
HCmed Innovations Co's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co (TPE:6934) has a EPS (Diluted) of NT$-0.85 as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on HCmed Innovations Co and its competitors.
Is HCmed Innovations Co's EPS (Diluted) too high?
HCmed Innovations Co's current EPS (Diluted) is NT$-0.85. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EPS (Diluted) compare to ABT and SYK?
HCmed Innovations Co's EPS (Diluted) of NT$-0.85 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Devices & Instruments company?
A good EPS (Diluted) depends on the Medical Devices & Instruments industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on HCmed Innovations Co and its competitors. HCmed Innovations Co's current EPS (Diluted) is NT$-0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EPS (Diluted) of NT$-0.85. The current EPS (Diluted) is NT$-0.85. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EPS (Diluted) is NT$-0.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score
Get the complete analysis for TPE:6934
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
